Archive

« Older Entries Newer Entries »

Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application Wednesday, October 9th, 2013
- Clinical studies from U.S. and Switzerland confirm previous performance data - Findings presented at DGHM/DGI 2013 and ICAAC 2013 Holzgerlingen, Germany, October 9, 2013 -- Curetis AG today announced the presenta [...]
Merus Secures €31 Million in Series B Round Extension Thursday, October 3rd, 2013
- Investment brings Series B to a total of €47.6 million - Johnson & Johnson Development Corporation joins as new investor; receives board seat Utrecht, The Netherlands, October 3, 2013 – Merus B.V., a biop [...]
ARGEN-X initiates phase Ib study of ARGX-111 in cancer Tuesday, September 17th, 2013
SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors Breda, the Netherlands, and Ghent, Belgium, September 17, 2013 – arGEN-X, a clinical stage human monoclonal antibody therapeutics compa [...]
Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Pa... Monday, September 16th, 2013
Heidelberg, Germany, and White Plains, NY, USA, September 16th, 2013: Affimed Therapeutics AG and The Leukemia & Lymphoma Society (LLS) today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM [...]
ARGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7 Thursday, September 12th, 2013
Breakthrough data to be presented during the ‘Discovery on Target’ conference in Boston, MA, USA on September 23, 2013 Breda, the Netherlands and Ghent, Belgium September 12, 2013 – arGEN-X, a clinical stage hu [...]
Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments Wednesday, August 28th, 2013
Raised $89.7M with successful IPO, providing substantial base to support development of Duchenne muscular dystrophy portfolio LEIDEN, The Netherlands (August 28, 2013) – Prosensa Holding N.V. (NASDAQ: RNA), the Dutc [...]
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH) Tuesday, July 30th, 2013
- MYDICAR When Inhaled May Restore Function of SERCA2a Enzyme in the Lungs to Reverse Deadly PAH Condition - SAN DIEGO, July 30, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company commit [...]
Kiadis Pharma to receive GMP manufacturing license and GMP certificate Tuesday, July 23rd, 2013
Amsterdam, The Netherlands, July 23, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the assoc [...]
Activaero’s partner ablynx initiated phase I studies in Respiratory Syncytial Virus (RSV) using favorite technology Thursday, July 18th, 2013
Gemuenden/Wohra, Germany, July 18, 2013 - Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partn [...]
Probiodrug Provides Update on Clinical Development of PQ912, its Most Advanced QC-inhibitor for Alzheimer’s Disease Tuesday, July 16th, 2013
HALLE/SAALE, Germany, July 16, 2013 – Probiodrug AG (Probiodrug) today provided an update on PQ912, an inhibitor of glutaminyl cyclase (QC) in clinical development for the treatment of individuals with Alzheimer’s di [...]

« Older Entries Newer Entries »

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries Newer Entries »

Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application Wednesday, October 9th, 2013
- Clinical studies from U.S. and Switzerland confirm previous performance data - Findings presented at DGHM/DGI 2013 and ICAAC 2013 Holzgerlingen, Germany, October 9, 2013 -- Curetis AG today announced the presenta [...]
Merus Secures €31 Million in Series B Round Extension Thursday, October 3rd, 2013
- Investment brings Series B to a total of €47.6 million - Johnson & Johnson Development Corporation joins as new investor; receives board seat Utrecht, The Netherlands, October 3, 2013 – Merus B.V., a biop [...]
ARGEN-X initiates phase Ib study of ARGX-111 in cancer Tuesday, September 17th, 2013
SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors Breda, the Netherlands, and Ghent, Belgium, September 17, 2013 – arGEN-X, a clinical stage human monoclonal antibody therapeutics compa [...]
Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma ... Monday, September 16th, 2013
Heidelberg, Germany, and White Plains, NY, USA, September 16th, 2013: Affimed Therapeutics AG and The Leukemia & Lymphoma Society (LLS) today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM [...]
ARGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7 Thursday, September 12th, 2013
Breakthrough data to be presented during the ‘Discovery on Target’ conference in Boston, MA, USA on September 23, 2013 Breda, the Netherlands and Ghent, Belgium September 12, 2013 – arGEN-X, a clinical stage hu [...]
Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments Wednesday, August 28th, 2013
Raised $89.7M with successful IPO, providing substantial base to support development of Duchenne muscular dystrophy portfolio LEIDEN, The Netherlands (August 28, 2013) – Prosensa Holding N.V. (NASDAQ: RNA), the Dutc [...]
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH) Tuesday, July 30th, 2013
- MYDICAR When Inhaled May Restore Function of SERCA2a Enzyme in the Lungs to Reverse Deadly PAH Condition - SAN DIEGO, July 30, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company commit [...]
Kiadis Pharma to receive GMP manufacturing license and GMP certificate Tuesday, July 23rd, 2013
Amsterdam, The Netherlands, July 23, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the assoc [...]
Activaero’s partner ablynx initiated phase I studies in Respiratory Syncytial Virus (RSV) using favorite technology Thursday, July 18th, 2013
Gemuenden/Wohra, Germany, July 18, 2013 - Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partn [...]
Probiodrug Provides Update on Clinical Development of PQ912, its Most Advanced QC-inhibitor for Alzheimer’s Disease Tuesday, July 16th, 2013
HALLE/SAALE, Germany, July 16, 2013 – Probiodrug AG (Probiodrug) today provided an update on PQ912, an inhibitor of glutaminyl cyclase (QC) in clinical development for the treatment of individuals with Alzheimer’s di [...]

« Older Entries Newer Entries »

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview